长期随访 KET-PD
对参加氯胺酮治疗帕金森病抑郁症 (KET-PD) 试验的受试者进行长期随访
The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.
研究概览
详细说明
This is a roll-out study from the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394). We will adopt an implementation science approach to have participants across ketamine and placebo groups in one of two arms: a) follow-up with treatment as usual (TAU) (at 3 and 6 months post-infusions); b) follow-up with 3 months of Cognitive Behavior Therapy (CBT) post-infusions, delivered remotely once per week, with follow-up assessments at 3 and 6 month timepoints. CBT is expected to have a superior sustained antidepressant response to the TAU follow-up group in both ketamine and placebo arms. We hypothesize that ketamine + CBT will show the most superior antidepressant response at follow-up.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- Yale New Haven Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
A total of n=56 participants with PD and comorbid depression, age 40-80, are being recruited under the parent clinical trial. As of July 2023, 20 participants have been enrolled. We aim to follow-up our remaining participants longitudinally and, within this, to have 20 prospective participants receive CBT, such that we will have 20 participants in each follow-up arm (CBT vs. TAU), and ultimately 10 in each group (ketamine + CBT, ketamine + TAU, placebo + CBT, placebo + TAU).
描述
Eligibility is determined in the ongoing parent clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Experimental: Ketamine Infusion
Participants who received 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394) |
Participants will receive 10 weeks of CBT Participants will receive standard of care treatment |
|
Placebo Comparator: Saline Infusion
Participants who received 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394) |
Participants will receive 10 weeks of CBT Participants will receive standard of care treatment |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Long-Term Change in Depression Severity
大体时间:3 Months and 6 Months
|
Change in MADRS score following course of ketamine vs. placebo treatment at 3 and 6 month timepoints; and change in MADRS across treatment (ketamine/placebo) and follow-up (CBT/TAU) arms at 3 and 6 month timepoints. The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression. |
3 Months and 6 Months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Apathy
大体时间:3 Months and 6 Months
|
Changes in apathy determined by the Starkstein Apathy Scale (SAS) scale |
3 Months and 6 Months
|
|
Change in Anxiety
大体时间:3 Months and 6 Months
|
Changes in anxiety determined by the State-Trait Anxiety Inventory (STAI) scale |
3 Months and 6 Months
|
|
Change in Parkinson's Symptom Severity
大体时间:3 Months and 6 Months
|
Changes in Parkinson's symptom severity determined by the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale |
3 Months and 6 Months
|
|
Change in Dyskinesia
大体时间:3 Months and 6 Months
|
Changes in dyskinesia determined by the Unified Dyskinesia Rating Scale (UDysRS) scale |
3 Months and 6 Months
|
|
Change in Pain
大体时间:3 Months and 6 Months
|
Changes in pain determined by the King's PD Pain Scale |
3 Months and 6 Months
|
|
Change in Fatigue
大体时间:3 Months and 6 Months
|
Changes in fatigue determined by the Parkinson's Fatigue Scale (PFS) |
3 Months and 6 Months
|
|
Change in Anhedonia
大体时间:3 Months and 6 Months
|
Changes in anhedonia determined by the Snaith-Hamilton Pleasure Scale (SHAPS) |
3 Months and 6 Months
|
合作者和调查者
合作者
调查人员
- 首席研究员:Sophie E. Holmes, PhD、Yale University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.